Author

M. Hayn

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:host-pathogen & immune response· 2 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1

Frequent Co-Authors

J. Muench· 3 shared C. M. Stuerzel· 2 shared F. Kirchhoff· 2 shared A. Bloetz· 1 shared A. Imhof· 1 shared A. N. Zelikin· 1 shared A. Rodriguez-Alfonso· 1 shared B. H. Hahn· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

J. Muench

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Potentiation of drug toxicity through virus latency reversal promotes preferential elimination of HIV infected cells

T. Truong, M. Hayn, C. Kaas Frich, L. K. Ladefoged, M. Jarlstad Olesen, J. Jakobsen, C. Lunaberg, B. Schiott, J. Muench, A. N. Zelikin

The paper demonstrates that latency reversal enhances the toxicity of HIV protease-activated toxins, preferentially eliminating HIV-infected cells in mixed populations.

bioRxiv · Jan 12, 2022Pharmacology & Toxicology

Natural Cystatin C fragments inhibit GPR15-mediated HIV and SIV infection without interfering with GPR15L signaling

M. Hayn, A. Bloetz, A. Rodriguez-Alfonso, S. Vidal, N. Preising, L. Staendker, S. Wiese, C. M. Stuerzel, M. Harms, R. Gross, C. Jung, M. Kiene, B. H. Hahn, T. Jacob, S. Poehlmann, , F. Kirchhoff

The paper identifies a Cystatin C fragment that inhibits GPR15-mediated HIV and SIV infection without affecting GPR15L signaling.

bioRxiv · Oct 26, 2020Microbiology

Imperfect innate immune antagonism renders SARS-CoV-2 vulnerable towards IFN-γ and -{lambda}

M. Hayn, M. Hirschenberger, L. Koepke, J. H. Straub, R. Nchioua, M. H. Christensen, S. Klute, C. Prelli Bozzo, W. Aftab, F. Zech, C. Conzelmann, J. A. Mueller, S. Srinivasachar Badarinarayan, C. M. Stuerzel, I. Forne, , K. M. J. Sparrer

This study identifies SARS-CoV-2's vulnerability to IFN-γ and -λ due to its inefficient antagonism of type I and II IFN responses, suggesting potential therapeutic strategies.

bioRxiv · Oct 15, 2020Microbiology